MedTrace Logo

Transplacental Transmission of COVID-19

NCT05124574 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-06-23

No results posted yet for this study

Summary

SARS-CoV-2, the agent responsible for pandemic COVID-19 infection, is transmitted mainly by respiratory droplets. Regarding maternal-fetal transmission, even if the mode of transmission from mother to fetus is not clear, some cases of perinatal transmission have been described, but without certainty on the routes of placental contamination, trans-cervical or by environmental exposure. .

The case described by J. Vivanti of a newborn with neonatal neurological involvement and whose mother had been infected during the last trimester of pregnancy reports possible transplacental transmission in a context of positive and elevated viremia in the mother and positive viremia in the newborn.

Conditions

Interventions

OTHER

Samples concern SARS-COV-2 + pregnant women at the time of childbirth

* nasopharyngeal PCR in the mother (performed systematically in this epidemic context), * Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology). * Sampling of amniotic fluid in case of cesarean section * Sampling of the placenta for histological and virological study.

OTHER

Samples concern newborns of SARS-COV-2 + mothers at birth

* In the birth room: * Collection of gastric fluid (PCR SARS-COV-2), * Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology). * In the newborn at D3 of life: \- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN. * In symptomatic newborns: * 1 yellow tube (SARS-COV-2 + RT-qPCR serology). * nasopharyngeal PCR,

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Hugues PATURAL, PhD · CHU SAINT-ETIENNE

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-03-02
Completion
2022-03-02

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05124574 on ClinicalTrials.gov